Due to their recommended use as first-line antidiabetic agents by the American Association of Clinical Endocrinologists (AACE), DPP-4 inhibitors are currently widely used as outstanding monotherapeutic or combination therapeutic agents for T2DM. Here, DPP4 is linked to type 2 diabetes mellitus.